Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase-1, Parallel-Design, Open-Label, Randomized, Multiple-Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3549492 in Healthy Participants With Overweight or Obesity

NCT07232732 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07232732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07232732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase-1, Parallel-Design, Open-Label, Randomized, Multiple-Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3549492 in Healthy Participants With Overweight or Obesity
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
October 27, 2025
Completion date
July 16, 2026
Enrollment
120 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, obesity, overweight